Therapeutic targets in lung tissue remodelling and fibrosis.

Liu, G; Philp, AM; Corte, T; Travis, MA; Schilter, H; Hansbro, NG; Burns, CJ; Eapen, MS; Sohal, SS; Burgess, JK; Hansbro, PM

Therapeutic targets in lung tissue remodelling and fibrosis.

Liu, G

Philp, AM Corte, T Travis, MA Schilter, H Hansbro, NG Burns, CJ Eapen, MS Sohal, SS Burgess, JK Hansbro, PM

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Pharmacology and Therapeutics, 2021, 225, pp. 1-34
Issue Date:: 2021-09

Closed Access

	Filename	Description	Size
	1-s2.0-S0163725821000413-main.pdf		3.46 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Liu, G https://orcid.org/0000-0002-0489-2638
dc.contributor.author	Philp, AM
dc.contributor.author	Corte, T
dc.contributor.author	Travis, MA
dc.contributor.author	Schilter, H
dc.contributor.author	Hansbro, NG
dc.contributor.author	Burns, CJ
dc.contributor.author	Eapen, MS
dc.contributor.author	Sohal, SS
dc.contributor.author	Burgess, JK
dc.contributor.author	Hansbro, PM
dc.date.accessioned	2022-02-07T02:27:53Z
dc.date.available	2021-03-03
dc.date.available	2022-02-07T02:27:53Z
dc.date.issued	2021-09
dc.identifier.citation	Pharmacology and Therapeutics, 2021, 225, pp. 1-34
dc.identifier.issn	0163-7258
dc.identifier.issn	1879-016X
dc.identifier.uri	http://hdl.handle.net/10453/154238
dc.description.abstract	Structural changes involving tissue remodelling and fibrosis are major features of many pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Abnormal deposition of extracellular matrix (ECM) proteins is a key factor in the development of tissue remodelling that results in symptoms and impaired lung function in these diseases. Tissue remodelling in the lungs is complex and differs between compartments. Some pathways are common but tissue remodelling around the airways and in the parenchyma have different morphologies. Hence it is critical to evaluate both common fibrotic pathways and those that are specific to different compartments; thereby expanding the understanding of the pathogenesis of fibrosis and remodelling in the airways and parenchyma in asthma, COPD and IPF with a view to developing therapeutic strategies for each. Here we review the current understanding of remodelling features and underlying mechanisms in these major respiratory diseases. The differences and similarities of remodelling are used to highlight potential common therapeutic targets and strategies. One central pathway in remodelling processes involves transforming growth factor (TGF)-β induced fibroblast activation and myofibroblast differentiation that increases ECM production. The current treatments and clinical trials targeting remodelling are described, as well as potential future directions. These endeavours are indicative of the renewed effort and optimism for drug discovery targeting tissue remodelling and fibrosis.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation	http://purl.org/au-research/grants/nhmrc/1175134
dc.relation.ispartof	Pharmacology and Therapeutics
dc.relation.isbasedon	10.1016/j.pharmthera.2021.107839
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.mesh	Airway Remodeling
dc.subject.mesh	Asthma
dc.subject.mesh	Calcium-Binding Proteins
dc.subject.mesh	Extracellular Matrix
dc.subject.mesh	Fibroblasts
dc.subject.mesh	Fibrosis
dc.subject.mesh	Glycoproteins
dc.subject.mesh	Humans
dc.subject.mesh	Idiopathic Pulmonary Fibrosis
dc.subject.mesh	Lung Diseases
dc.subject.mesh	Matrix Metalloproteinases
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Transforming Growth Factor beta
dc.subject.mesh	Airway Remodeling
dc.subject.mesh	Asthma
dc.subject.mesh	Calcium-Binding Proteins
dc.subject.mesh	Extracellular Matrix
dc.subject.mesh	Fibroblasts
dc.subject.mesh	Fibrosis
dc.subject.mesh	Glycoproteins
dc.subject.mesh	Humans
dc.subject.mesh	Idiopathic Pulmonary Fibrosis
dc.subject.mesh	Lung Diseases
dc.subject.mesh	Matrix Metalloproteinases
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Transforming Growth Factor beta
dc.subject.mesh	Extracellular Matrix
dc.subject.mesh	Fibroblasts
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Lung Diseases
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Fibrosis
dc.subject.mesh	Matrix Metalloproteinases
dc.subject.mesh	Glycoproteins
dc.subject.mesh	Transforming Growth Factor beta
dc.subject.mesh	Calcium-Binding Proteins
dc.subject.mesh	Idiopathic Pulmonary Fibrosis
dc.subject.mesh	Airway Remodeling
dc.title	Therapeutic targets in lung tissue remodelling and fibrosis.
dc.type	Journal Article
utslib.citation.volume	225
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-02-07T02:27:51Z
pubs.publication-status	Published
pubs.volume	225

Abstract:

Structural changes involving tissue remodelling and fibrosis are major features of many pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Abnormal deposition of extracellular matrix (ECM) proteins is a key factor in the development of tissue remodelling that results in symptoms and impaired lung function in these diseases. Tissue remodelling in the lungs is complex and differs between compartments. Some pathways are common but tissue remodelling around the airways and in the parenchyma have different morphologies. Hence it is critical to evaluate both common fibrotic pathways and those that are specific to different compartments; thereby expanding the understanding of the pathogenesis of fibrosis and remodelling in the airways and parenchyma in asthma, COPD and IPF with a view to developing therapeutic strategies for each. Here we review the current understanding of remodelling features and underlying mechanisms in these major respiratory diseases. The differences and similarities of remodelling are used to highlight potential common therapeutic targets and strategies. One central pathway in remodelling processes involves transforming growth factor (TGF)-β induced fibroblast activation and myofibroblast differentiation that increases ECM production. The current treatments and clinical trials targeting remodelling are described, as well as potential future directions. These endeavours are indicative of the renewed effort and optimism for drug discovery targeting tissue remodelling and fibrosis.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/154238